Patent 9012443 was granted and assigned to Amgen on April, 2015 by the United States Patent and Trademark Office.
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.